Nathan Ihle joined Bolt Biotherapeutics in December 2019 as Vice President, CMC & Quality. In this role he is responsible for building and leading the CMC Development and Quality groups and coordinating a network of outsourced manufacturers. Prior to joining Bolt, Nathan held positions of increasing responsibility at Merck, PathoGenesis, Celltech, Seattle Genetics, and Immunomedics. While at Seattle Genetics he led the CMC team responsible for the development and commercialization of ADCETRIS® (brentuximab vedotin).
Through his career, Dr. Ihle has been a key contributor to the development of six approved drugs and numerous ADCs currently in clinical development. He is trained as a synthetic organic chemist, with degrees from Whitman College and Stanford University. He conducted postdoctoral research at the University of California, Berkeley.
- Primary/Complementary Interactive Styles: Expert/Warrior
- Interactive Combination: The Specialist
- In a film, he’d be played by: Morgan Freeman
- Common Leadership Characteristic: Mentors others with knowledge
